Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited and Seattle Genetics, Inc. , today announced the initiation of an international pivotal phase 3 clinical trial evaluating ADCETRIS in patients with CD30-expressing cutaneous T-cell lymphoma who received at least one prior systemic therapy.
